HSGX Histogenics Corporation

0  1%
Previous Close 0.12
Open 0.12
Price To Book -0.76
Market Cap 11569531
Shares 94,599,601
Volume 4,282,076
Short Ratio
Av. Daily Volume 7,498,787

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Development to be suspended - noted December 21, 2018.
Cartilage defects in the knee

Latest News

  1. Edited Transcript of HSGX earnings conference call or presentation 9-Nov-17 1:30pm GMT
  2. Biotech Bounce Just Getting Started
  3. Jonathan Lieber Joins Danforth Advisors as Managing Director
  4. Biotech Stocks on the Rise
  5. Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?
  6. Best Ways to Play Biotech Rally
  7. The Next Big Biotech Breakout
  8. 4 Healthcare Stocks To Watch On Friday (1/4/19)
  9. Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway
  10. Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway
  11. New Research Coverage Highlights Intersections, PRGX Global, Ecology and Environment, Histogenics, SeaChange International, and TransAct Technologies — Consolidated Revenues, Company Growth, and Expectations for 2018
  12. Cell therapy biotech Vericel eyes $2B knee repair market
  13. Histogenics: 3Q Earnings Snapshot
  14. Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results
  15. Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway
  16. What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price
  17. Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics